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Abstract
A systematic review of the literature was performed to provide a comprehensive overview of the available
decision support tools for incurable metastatic colorectal cancer, and to assess their clinical usefulness. We
identiﬁed 14 tools. The evidence regarding the quality of the information they provide is too limited to currently
recommend their use to guide treatment decision-making.
Background: Decision-making regarding palliative treatment for patients with metastatic colorectal cancer (mCRC) is
complex and comprises numerous decisions. Decision-making should be guided by the premise of maintaining and/or
improving patients’ quality of life, by patient preference, and by the trade-off between treatment beneﬁts and harm.
Decision support systems (DSSs) for clinicians (eg, nomograms) can assist in this process. The present systematic
review aimed to provide a comprehensive overview of the available DSSs for incurable mCRC and to assess their
clinical usefulness. Materials and Methods: A systematic literature search was performed in PubMed, Embase, and
the Cochrane Library. We extracted information on the DSS characteristics and their discriminatory ability, calibration,
and user-friendliness. Results: From 5205 studies, we identiﬁed 14 DSSs for decisions regarding palliative resection
of the primary tumor (n ¼ 3), radiotherapy for metastases (n ¼ 2), treatment type (invasive vs. symptomatic only; n ¼ 7),
and selection of chemotherapy (n ¼ 2). The predictors varied greatly among the DSSs, and only 1 DSS incorporated a
genetic marker (ie, UGT1A1). None of the DSSs included > 1 treatment option, nor did any DSS present estimates of
treatment beneﬁts and harms. Five tools had not been externally validated, two had only been validated in < 35
patients, and the rest had only been validated in populations similar to the population used for their development.
Discriminatory accuracy was generally moderate to poor. Calibration measures were only reported for 2 tools.
Conclusion: A limited number of DSSs are available to support palliative treatment decisions for patients with mCRC,
and the evidence regarding their discriminatory ability and calibration is too limited to recommend their use. New DSSs
comparing multiple treatment options and presenting both treatment beneﬁts and harms are needed.
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Clinical Usefulness of Decision-making ToolsIntroduction
Colorectal cancer (CRC) is the third most common cancer in
men and the second most common cancer in women. Worldwide,
in 2012, 9% to 10% of all incident cancer cases in men and
women were CRC. Approximately one quarter of CRC patients
will have metastatic disease at diagnosis, and approximately 50%
of CRC patients with early-stage disease will develop metastases
during follow-up.1 CRC mortality varies greatly by disease stage,
with stage I patients having, on average, 5-year survival rates >
90% and those with metastatic disease 5-year survival rates of 10%
to 20%.2 However, great variation also exists in the survival among
patients with metastatic CRC (mCRC), because some patients will
still be eligible to undergo surgery with curative intent. For
example, recent studies have reported 5-year survival rates of 25%
to 40% for mCRC patients with resectable liver metastases.1,3
Also, for those with successfully resected peritoneal metastases,
5-year survival rates of  50% have been reported.3,4 However,
most mCRC patients will have either permanently unresectable
metastases or local recurrence and therefore will not be eligible to
receive (further) curative treatment. In this population, treatment
has a palliative intent. Palliative care, as deﬁned by the World
Health Organization, primarily aims to improve the quality of life
of patients through the early identiﬁcation, assessment, and
treatment of physical, psychosocial, and spiritual issues.5 Palliative
care can consist of treatments directed at limiting tumor growth
and associated symptoms (eg, pain) and treatments solely intended
to relieve symptoms (ie, physical, emotional, and spiritual).
Although cure is no longer possible, treatments directed at limiting
tumor growth can prolong patients’ life (which, in the case of
mCRC, can result in a median overall survival beneﬁt > 2 years).
However, systemic treatments directed at limiting tumor growth
are also associated with side effects that can affect patients’ quality
of life.
Decision-making about palliative care for CRC is complex and
multifaceted. These decisions are often preference-sensitive (ie, no
single choice is “best” from a medical perspective). It is imperative
to ﬁnd the right balance between maximizing length of life and
optimizing quality of life to reach a decision that best matches the
patient’s goals and preferences. The complexity results in part from
the many possible treatment combinations, and the heterogeneity of
the patient population with respect to, for example, the location of
the metastases and the resectability of the primary tumor. Decision
support systems (DSSs), which generate case-speciﬁc treatment
advice, can help oncologists to present the options to their patients
and better weigh the trade-off between the beneﬁts and harms of
palliative treatment. DSSs would ideally compare multiple treat-
ment options and predict the outcomes, such as survival and
potential treatment gains in terms of survival, toxicity, and cost-
effectiveness. Currently, a comprehensive overview of published
DSSs to guide clinical decision-making about palliative treatment
for incurable mCRC is lacking. Research has mainly focused on the
development of tools to inform decision-making about treatments
with curative intent (especially surgical treatment) and/or deter-
mining whether treatment with curative intent is still feasible for
patients with mCRC. Furthermore, the available reviews of DSSs
for treatment decision-making used a limited search strategy, onlyClinical Colorectal Cancer March 2018focused on 1 type of tool (eg, Kawai et al6 focused on available
nomograms to help CRC treatment decision-making), or only
focused on 1 speciﬁc clinical decision (eg, Tokuhashi et al7 focused
on DSSs for treatment decision-making about spinal metastases).
We, therefore, conducted a systematic search of published DSSs for
decision-making about palliative treatment for patients with
incurable CRC. We have provided an overview of the characteristics
of the DSS (eg, purpose, predictors, and type of tool); level of ev-
idence regarding the DSSs’ discriminatory accuracy and calibration;
and the user-friendliness of the DSSs.
Materials and Methods
Systematic Literature Search
In collaboration with an experienced information specialist
(E.P.J.), a systematic literature search was performed to identify all
relevant studies in the bibliographic databases PubMed, EMBASE,
and the Cochrane Library (via Wiley) from inception to February
23, 2016. The search terms included controlled terms from MeSH
in PubMed, EMtree in Embase, and free text terms only in the
Cochrane Library. Search terms expressing “colorectal cancer”
were combined with search terms comprising “decision support
systems” and “prognosis” (the detailed search strategy is provided
in Table 1). The references of the identiﬁed reports were searched
for additional relevant studies. In addition to our search of the
bibliographic databases, we searched the websites of the American
Society of Clinical Oncology, National Institute for Health and
Care Excellence, National Comprehensive Cancer Network,
European Society for Medical Oncology, and the DSS indexing
website (www.MedicalAlgorithms.com) for references to addi-
tional DSSs.
Selection Process
The aim of our search was to identify available complete DSSs
(not individual predictors) to aid decision-making regarding
palliative treatment for patients with incurable mCRC. Tools not
speciﬁcally developed for decision-making for incurable mCRC
that had been validated in this patient population were also
eligible for inclusion. DSSs for decision-making regarding sur-
gery, radiotherapy, and/or systemic therapy for incurable mCRC
were eligible for inclusion. Also eligible were DSSs marking the
transition from palliative care, including treatment directed at
limiting tumor growth to noninvasive treatment for symptom
relief only.
The titles and abstracts were screened by 3 of us (E.G.E.,
H.C.W.d.V., and J.J.T.) independently, and discrepancies were
resolved through consensus. After the identiﬁcation of potentially
relevant studies, 1 of us (E.G.E.) made the ﬁnal selection of DSSs by
screening the full text reports; when in doubt, 3 of us (H.C.W.d.V.,
J.J.T., and V.M.H.C.) were consulted. Because the aim of the
present study was to assess the usefulness of available tools in current
clinical practice, DSSs only developed and/or validated in patient
populations not treated according to current guidelines and those
predicting prognosis with treatments no longer in use were
excluded. To ensure that the information derived from the devel-
opment and validation studies assessed in the present review is
relevant for current clinical practice, we applied time restrictions
Table 1 Detailed Search Strategy for Each Database
Database Search Terms
PubMed “Colonic neoplasms” [MeSH] OR “colorectal neoplasms” [MeSH] OR colonic neoplasm*[tiab] OR colon neoplasm*[tiab] OR “cancer of colon”[tiab] OR
“cancer of the colon”[tiab] OR colon cancer*[tiab] OR colonic cancer*[tiab] OR colorectal neoplasms*[tiab] OR colorectal tumor*[tiab] OR colorectal
tumour*[tiab] OR colorectal carcinoma*[tiab] OR colorectal cancer*[tiab] AND “decision support systems, clinical” [MeSH] OR “decision support
techniques” [MeSH] OR “nomograms” [MeSH] OR “Markov chains” [MeSH] OR decision support system*[tiab] OR decision support technique*[tiab]
OR decision aid*[tiab] OR decision support model*[tiab] OR decision analys*[tiab] OR decision modeling[tiab] OR nomogram*[tiab] OR prediction
rule*[tiab] OR (prognos*[tiab] AND (index[tiab] OR score*[tiab] OR model*[tiab])) OR markov[tiab] AND (“prognosis” [MeSH:noexp] OR
“incidence” [MeSH Terms:noexp] OR mortality [MeSH terms] OR follow up studies [MeSH:noexp] OR prognos*[tiab] OR predict*[tiab] OR
course*[tiab] OR mortalit*[tiab]) OR “life expectancy”[MeSH] OR “survival rate”[MeSH] OR “longevity”[MeSH] OR “longevity”[tiab] OR “life expectancy”
[tiab] OR “life expectance”[tiab] OR “life expectation”[tiab] OR “survival”[tiab] OR prognos*[tiab] OR (toxicit*[tiab] OR toxic potential*[tiab] OR
“margin of safety”[tiab] OR adverse effect*[tiab] OR survival[tiab])
Embase “colon tumor”/exp OR “colorectal tumor”/exp OR “colonic neoplasm*”:ab,ti OR “colon neoplasm*”:ab,ti OR “cancer of colon”:ab,ti OR
“cancer of the colon”:ab,ti OR “colon cancer*”:ab,ti OR “colonic cancer*”:ab,ti OR “colorectal neoplasms*”:ab,ti OR “colorectal tumor*”:ab,ti OR
“colorectal tumour*”:ab,ti OR “colorectal carcinoma*”:ab,ti OR “colorectal cancer*”:ab,ti AND “decision support system”/exp OR “nomogram”/exp OR
“probability”/exp OR “decision support system*”:ab,ti OR “decision support technique*”:ab,ti OR “decision aid*”:ab,ti OR “decision support
model*”:ab,ti OR “decision analys*”:ab,ti OR decision AND modeling:ab,ti OR “prediction rule*”:ab,ti OR probabilit*:ab,ti OR nomogram*:ab,ti OR
(prognos*:ab,ti AND (index:ab,ti OR score*:ab,ti OR model*:ab,ti)) OR markov:ab,ti AND “prognosis”/exp OR “incidence”/exp OR “mortality”/exp
OR “follow up”/exp OR predict*:ab,ti OR course*:ab,ti OR mortalit*:ab,ti OR “life expectancy”/exp OR “survival rate”/exp OR “longevity”/exp OR
“longevity”:ab,ti OR “life expectancy”:ab,ti OR “life expectance”:ab,ti OR “life expectation”:ab,ti OR “survival”:ab,ti OR prognos*:ab,ti OR toxicit*:ab,ti
OR “toxic potential*”:ab,ti OR “margin of safety”:ab,ti OR “adverse effect*”:ab,ti AND (“article”/it OR “article in press”/it OR “review”/it)
Cochrane
Library
“Incidence” OR mortality OR follow up studies OR prognos* OR predict* OR course* OR mortalit* OR “life expectancy” OR “longevity” OR
“life expectancy” OR “life expectance” OR “life expectation” OR “survival” OR toxicit* OR toxic potential* OR “margin of safety” OR adverse
effect* OR survival:ti,ab,kw AND “decision support system*” OR “decision support technique*” OR “decision aid*” OR “decision support model*” OR
“decision analys*” OR “decision modeling OR prediction rule*” OR nomogram* OR (prognos* and (index or score* or model*)) or markov:ti,ab,kw AND
“colonic neoplasm*” OR “colon neoplasm*” OR “cancer of colon” OR “cancer of the colon” OR “colon cancer*” OR “colonic cancer*” OR “colorectal
neoplasms*” OR “colorectal tumor*” OR “colorectal tumour*” OR “colorectal carcinoma*” OR “colorectal cancer*”:ti,ab,kw
Table 2 Time Restrictions for Data Searcha
Outcome
Cutoff Diagnosis
Yearb
Prognosis in general 2006
Prognosis postoperatively (colon cancer) 1985
Prognosis postoperatively (rectal cancer) 2001
Selection of patients for palliative resection of primary
tumor in presence of unresectable metastases
2006
Prognosis with and without radiotherapy 1985
Prognosis with and without systemic therapy 2006
Risk of developing side effects 2006
Selection of optimal treatment strategy 2006
aDecision support systems were eligible for inclusion if they were developed and/or validated in
patients with colorectal cancer diagnosis.
bCutoffs were determined by when the last major changes in treatment advice were introduced
in the Dutch treatment guidelines (which roughly coincided with international guidelines).
Ellen G. Engelhardt et al(Table 2) using the last major changes in treatment advice intro-
duced in the 2014 Dutch treatment guidelines,8 which roughly
coincided with international guidelines (eg, European Society for
Medical Oncology guidelines9).
Search for Additional Studies
After the ﬁnal selection of DSS, a manual search was performed for
each DSS to identify reports describing its development, validation,
and/or any updates. Reviews found using the search strategy and the
“cited by” function in PubMed were used to ﬁnd additional studies.
We also performed a manual search in PubMed to identify validation
studies for each DSS using the following terms: (name of the DSS)
AND (terms for colorectal cancer [Table 1]) AND (validat*). One of
us (E.G.E.) screened all identiﬁed additional reports and made the
ﬁnal selection. Doubts regarding the selection of studies were
resolved through consensus (H.C.W.d.V., J.J.T., V.M.H.C.).
Data Extraction
An overview of the data extracted from the full text reports is
provided in Table 3. Model performance assessment was deter-
mined by the ﬁndings of the validations and described using mea-
sures for discriminative ability (eg, C-index). The methods used to
determine model calibration were classiﬁed using the levels
described by Van Calster et al.11 The level of evidence for the
discriminatory accuracy and calibration of the DSSs is described
using the levels of evidence reported by Reilly and Evans.12 Eval-
uation of the user-friendliness of the DSS was based on whether the
predictors were routinely collected, ease of use (eg, availability of a
nomogram or online tool), and accessibility (eg, freely accessible or
access by subscription only). Data extraction was performed by 1 of
us (E.G.E.), with 3 of us (H.C.W.d.V., J.J.T., V.M.H.C.) con-
sulted when in doubt.Results
The literature search yielded 5205 unique reports, from which we
identiﬁed 14 DSSs developed to aid treatment decision-making for
patients with incurable mCRC (Figure 1). No additional references
were found from the websites of the professional groups. A graphic
overview of the DSSs identiﬁed is shown in Figure 2, categorized by
the type of treatment and their purpose.
DSS Characteristics
A detailed overview of the characteristics of the
DSSs, including their development, output, validation, and
user-friendliness, is provided in Table 4. We identiﬁed 10
prognostic scores,13-15,17-20,22-24 3 nomograms,16,21,25 and 1
chemotherapy sensitivity and resistance assay.26 Of the 14 tools,Clinical Colorectal Cancer March 2018 - e3
Table 3 Data Extraction From Included Reports
Category Description of Items
Development population Description of the study population
Number of patients in the population
Years of diagnosis of the study population
Setting
Study design
Aim Purpose of DSS as stated by developers
Predictors Predictors included in DSS
Output Is the model presented as a nomogram
If presented as risk categories, how many were included
Description of prognostic categories
Prognosis for patients in the risk categories
Validation population Description of the study population
Number of patients
Years of diagnosis for the study population
Setting
Study design
Model performance
Discriminative ability A measure for the extent to which the DSS is able to discriminate between 2 outcomes or conditions (eg, death vs. alive);
ﬁndings from external validations (if available) are described; if included in the study, the area under the curve or
C-statistics is reported; interpretation of C-index: <0.6, poor; 0.6-0.7, moderate; 0.7-0.8, strong; >0.8, very strong10
van Calster levels of calibration11 These levels indicate the methodologic soundness of the method used to determine model calibration:
1. Mean calibration method: comparison of average predicted risk to average observed risk
2. Weak calibration method: assessment of the presence of systematic over- or underﬁtting using regression analyses
3. Moderate calibration method: comparison between deciles of predicted and observed outcomes
4. Strong calibration method: comparison of event rate to predicted risk for all possible combinations of covariates
Reilly levels of evidence12 Measure for how thoroughly the DSS is validated:
Level 1: derivation from a prediction model and not yet externally validated
Level 2: narrow validation in one setting
Level 3: broad validation in varied settings and populations
Level 4: narrow impact analysis of model as decision rule in one setting
Level 5: broad impact analysis of model as decision rule in varied settings and populations
User-friendliness
Predictors routinely collected Are the predictors in the DSS routinely collected in clinical practice
Ease of use Is it easy to apply the tool (eg, scoring system is easily derived from the report)
Online tool available Is an online tool available
Abbreviation: DSS ¼ decision support system.
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e4 -10 were developed in the previous 5 years (ie, after 2011). Six of
the DSSs had focused on patients with either brain or skeletal
metastases.17-22 Eight of the DSSs identiﬁed were developed and/
or only validated in Asian13-15,25 or European pop-
ulations.16,20,21,26 Furthermore, great variation was found in the
factors included in the DSSs. Only 3 factors were incorporated in
> 2 DSSs (ie, patient age, performance status, and distant
metastasis location; Figure 3). The variation in predictors among
the DSSs was not fully explained by the DSSs having different
aims or because they focused on speciﬁc subgroups of incurable
mCRC patients (Table 4).
The DSSs we identiﬁed only focused on one side of the trade-off
involved in decision-making—predominantly, the beneﬁts of
treatment (n ¼ 10). None presented information on the expected
treatment beneﬁt and risks of side effects or, for example, theClinical Colorectal Cancer March 2018expected quality adjusted life expectancy. Also, none of the DSSs
compared different treatment options. Five of the DSS aimed to
help oncologists decide whether one speciﬁc treatment would be
worthwhile, given the patients’ expected survival period.13-16,22
Seven other DSSs aimed to inform oncologists’ evaluation
regarding whether it would be worthwhile to pursue invasive
treatment options in general, given the patients’ prognosis.17-21,23,24
One DSS aimed to help oncologists select the most effective
chemotherapy regimen.26 Finally, 1 DSS aimed to help oncologists
select patients likely to develop a severe side effect a priori to take
preventive measures.25
Level of Evidence for DSSs
Generally, the tools were developed and validated in non-
randomized populations of patients that had received the same
Figure 1 Flowchart of Systematic Literature Search and Article Selection
Articles retrieved
Total number of articles scanned 
after removing duplicates
N=5205
Exclusion based on title and abstract
N=5080
Selection for full text retrieval
N=125
Exclusions based on full text
N=117
- Curative treatment intent (N=60)
- Data used too old (N= 12)
- Determining feasibility of curative treatment (N=5)
- Not a tool (N=9)
- Treatment modality no longer used (N=1)
- Review for reference tracking (N=6)
- No fulltext available (N=9)
- Development and/or validation population consisted of <20 
colorectal cancer patients with incurable disease (N=15)
PUBMED
N=3690
EMBASE
N=4202
Number of articles included
N= 14
Cochrane
Database Library 
N=322
Total number of articles retrieved with 
search for additional validation 
studies of included DSS
N=6
Number of DSS included
N=14
Abbreviation: DSS ¼ decision support system.
Ellen G. Engelhardt et altreatment. Only 1 study had included a control group.26 Of the 14
DSSs identiﬁed, 5 were not externally validated. Calibration mea-
sures were only reported in 2 validation studies.21,25 We did not
identify any impact studies for any of the DSSs included. Of the 14
DSSs, 9 only achieved the lowest level of evidence (ie, Reilly level 1).
The other 5 DSSs reached a Reilly level of evidence of 2 (Table 4). In
the next sections, we describe the DSSs identiﬁed according to their
purpose and present the available data regarding the level of evidence.
DSS Predicting Prognosis in General. The Glasgow Prognostic
Score (GPS) was developed using a cohort of incurable lung cancerpatients to predict the prognosis in general (Table 4).23 We found
many studies in which the GPS was evaluated, including studies of
incurable metastasized CRC. Most of these studies aimed to eval-
uate whether the GPS is a predictor of survival that could be
incorporated into a DSS, not whether it can be used as a DSS on its
own. Also, the data used in a number of studies was too old.
Therefore, only the study by Maillet et al28 met our inclusion
criteria. Their study showed that the GPS is an independent
prognostic tool in a population of incurable CRC patients treated
with chemotherapy and bevacizumab.28 In the multivariate analysis,
only GPS remained as a signiﬁcant factor. The GPS was reported toClinical Colorectal Cancer March 2018 - e5
Figure 2 Overview of Published Tools to Aid Palliative Treatment Decisions for Patients With Incurable Colorectal Cancer
Patients with incurable colorectal cancer
(i.e., inoperable primary tumor, recurrence 
and/or inoperable distant metastases)
Primary tumor or 
local recurrence
Palliative tumor 
resection
Systemic treatment 
for inoperable tumor
Inoperable distant 
metastases (e.g., liver, 
peritoneal and lung)
- Relieving and/or preventing symptoms due to the tumor load
- In emergency situations (e.g., obstructive ileus)
- Evidence on survival gain of palliative surgery is inconclusive
- Palliative chemotherapy (5-fluorouracil-, irinotecan- or oxaliplatin-based) in 
combination with biological therapy (e.g., bevacizumab) to reduce the tumor 
load and symptom relief. 
- Targeted therapy: anti-epidermal growth factor receptor (EGFR) antibody 
therapy for patients with a mutated KRAS-gene
Radiation treatment
Systemic treatment
To reduce the tumor load and symptom relief:
- External beam radiotherapy 
- Radiofrequency ablation
- Radioembolization
- Palliative chemotherapy (5-fluorouracil-, irinotecan- or oxaliplatin-based) in 
combination with biological therapy (e.g., bevacizumab) to reduce the tumor 
load and symptom relief. 
- Targeted therapy: anti-epidermal growth factor receptor (EGFR) antibody 
therapy for patients with a mutated KRAS-gene
Radiation treatment - External beam radiotherapy (more often for rectal cancer) to reduce the tumor load and symptom relief
Marking transition 
between supportive 
care and more 
invasive palliative 
treatment
Supportive care consists of treatments aiming to:
- reduce physical symptoms (e.g., pain, fatigue, loss of appetite, nausea, and 
insomnia) such as pharmaceutical, nutrition, or physical therapy
- conserve and/or improve emotional and spiritual well-being such as counseling, 
and support groups
 Dorajoo score
AAAP score
Maeda score
● GPS
 mGPS
 Ichikawa nomogram
♣ Oncogramme
 RPA
 GPA
 Rades BM score
 Dziggel score
 Pietrantonio nomogram
 Fendler nomogram
 Rades MSCC score
● GPS
 mGPS
 Ichikawa nomogram
♣ Oncogramme
= predicting prognosis; = selection of patients for treatment;= predicting probability of side-effects manifesting; ♣ determining tumor response to chemotherapeutic agents
MSCC= metastatic spinal cord compression; BM= brain metastases; mGPS= modified Glasgow Prognostic score; GPS= Glasgow Prognostic score
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e6 -discriminate among patients with good, moderate, and poor prog-
nosis (Table 4). However, the methods used to determine the GPS’
discriminatory accuracy were not optimal, and model calibration
was not assessed.
DSS Selecting Patients for Whom Treatment Could Be Worthwhile.
Fendler et al16 developed a nomogram to predict the probability of
1-year survival for CRC patients with inoperable liver metastases
after treatment with selective internal radiation therapy (Table 4).
Currently, little can be reported about the performance of this
nomogram, because the validation population consisted of only 25
patients.16
Three of the DSSs aimed to aid decision-making regarding
elective resection of the primary tumor if the patients have unre-
sectable distant metastases, the AAAP (ie, age, alkaline phosphatase,
ascites, platelet/lymphocyte ratio) score,13 the score by Dorajoo
et al,14 and the score by Maeda et al.15 Although developed to
support the same decision, different predictors were incorporated
into these tools, and they predicted different outcomes (Table 4).
For example, the AAAP score predicts the probability of 2-year
overall survival, and the Dorajoo score predicts cancer-speciﬁc sur-
vival. All 3 tools were developed in Asian patient populations. Only
the Dorajoo score was externally validated, although also in an Asian
population. The concordance probability estimate in the validation
study was 0.65 and the time-dependent discriminatory accuracies
ranged from 0.70 to 0.75 (Table 4). No calibration measures wereClinical Colorectal Cancer March 2018reported for the Dorajoo score.14 No consensus has been reached on
whether resection of the primary tumor yields a survival beneﬁt for
patients with unresectable metastases, although a recent study has
shown that that might be the case.30
McMillan et al24 developed a modiﬁed version of the GPS
(mGPS; Table 4), which has also been evaluated in numerous
studies. Except for 1 study,29 all were excluded because they
assessed whether the mGPS was a potentially relevant component
of a DSS and not whether it was an independent tool. Ishizuka
et al29 investigated the prognostic value of the mGPS in a pop-
ulation of CRC patients with an unresectable primary tumor and/
or unresectable metastases undergoing palliative chemotherapy
(Table 4). In the multivariate analysis, only mGPS remained as a
signiﬁcant factor and seemed to be able to discriminate among the
3 prognostic categories (Table 4). However, the Kaplan-Meier
survival curves for the mGPS score 0 and 1 categories over-
lapped, suggesting that reevaluation of the cutoffs used in the
scoring system might be required. The methods used to assess the
mGPS’ discriminatory accuracy were not optimal, and its cali-
bration was not assessed.
We included tools developed to select patients with incurable
mCRC who would be likely to beneﬁt most from more invasive
treatment of brain metastases. These included recursive partitioning
analysis (RPA),17 the graded prognostic assessment (GPA),18 the
nomogram by Pietrantonio et al,21 the score by Dziggel et al,19 and
the score by Rades et al20 (Table 4).
Table 4 Detailed Overview of Characteristics, Purpose, Output, and Performance of Decision Support Tools Identiﬁed
Variable
Name of Tool (Publication Date)
AAAP
Score13
(2015)
Dorajoo
Score14
(2015)
Maeda
Score15
(2013)
Fendler
Nomogram16
(2015)
RPA,17 GPA18
(1997, 2008)
Dziggel
Score19
(2014)
Rades BM
Score20
(2015)
Pietrantonio
Nomogram21
(2015)
Rade SCC
Score2 2012)
GPS,23 mGPS24
(2003, 2007)
Ichikawa
Nomogram25
(2015)
Oncogramme26
(2016)
Development
population
Population CRC, SYN,
UR Met, ER
of PT
CRC, UR Met,
elective resection
of PT
CRC, ASX PT,
UR Met
CRC, UR liver Met
refractory to CTx
Cancer with BMa Cancer with BMs
from less RS
tumors treated
with WBRT
CRC 3 BMmax
after STS
CRC, SYN or
MC BM
CRC, imp d motor
funct rom
MS RT
UR lung cancera Advanced CRC,
irinotecan-containing
CTx
Stage IV CRC (curable
and incurable), 5-FU,
FOLFOX or FOLFIRI
Patients (n) 110 379 94 100 1200 (CRC not
known)
34 CRC 19 227 161 1312 19
Years of diagnosis 2003-2012 1999-2005 2001-2009 2003-2010 1979-1993 NR 2000-2014 2000-2013 1997-2002 2009-2012 2011-2012
Setting 1 Hospital, China 1 Hospital,
Singapore
1 Hospital, Japan 1 Hospital,
Germany
3 Clinical trials
(RTOG 79-16,
RTOG 85-28,
RTOG 89-05)
NR 2 Hospitals,
Germany
8 Hospitals, Italy 1 Hospital, UK 299 Institutions,
Japan
1 Hospital, France
Study design Retro Retro Retro Retro Retro Retro Retro Retro R Retro Prosp, Observ Prosp, PoC
DSS purpose
Predicted
outcome
2-y OS CSS OS 1-y OS OS 6-mo OS 6- and 12-mo OS OS 6-m S OS Probability of severe
neutropenia
(cycle 1)
Chemotherapy
sensitivity and
resistance
Treatment
decision
Whether to
perform ER
of PT
Whether to
perform ER
of PT
Whether or to
perform ER of PT
Whether to
perform SIRT
Selecting optimal
treatment strategy
(invasive vs. BSC)
Selecting optimal
treatment strategy
(invasive vs. BSC)
Whether to
perform follow-up
treatment; which
is best
Selecting optimal
treatment strategy
(invasive vs. BSC)
Whethe use RT Not treatment-speciﬁc;
prediction of prognosis
to guide general
treatment decisions
Choice of
chemotherapy
regimen; adjustment
of doses
Choice of most
effective treatment
Predictors Age; ALP,
ascites, PLR
Age, albumin,
CEA, distant Met
location, histologic
tumor grade
PS, GPS, NLR,
Met extent
Previous liver
surgery, CEA,
transaminase,
diameter of 2
largest Met
EC Met, KPS,
age, no. of BMsa,
no PD of PTb,c,
GPA, RPAc
Age, KPS, EC Met EC Met, KPS,
interval from BM
diagnosis and
STS
Age, KPS, BM
location, BM no.
ECOG P isceral
Met, m y level
before R ming of
motor ction
imp ent
CRP, albumin Mono or
combination CTx,
initial irinotecan dose,
age, sex, UGT1A1
genotype, ECOG PS,
bilirubin, ANC
NA, tumor tissue
exposed to CTx
Output
Prognostic
categories
3 3 3 NA RPA: 3
GPA: 4
3 4 NA GPS/mGPS: 3 NA NA
Description Risk of death:
low, 0 risk factors;
moderate, 1- 2;
high, 3-4 factors
Prognosis: good,
0-3 score;
moderate, 4- 7;
poor, >7 score
Risk of death:
low, 0 risk factors;
moderate: 1- 2;
high, 3-4 factors
NA RPA: class I, only
good prognostic
factors; class II,
other patient; class
III, KPS <70
GPA: class I,
good; class II,
intermediate to
good; class III,
intermediate to
poor; class IV, poor
Prognosis: poor: 5-
8 score; moderate,
9-11 score; good:
>11 score
Prognosis: poor,
score 0; moderate
to poor, score 1;
moderate to good,
score 2; good,
score 3
NA Prognosis or: 8-12
score; m rate to
poor, 13 score;
modera good,
20-23 s ; good,
24-2 ore
Score 0, no risk
factors; score 1,
1 risk factor; score 2,
2 risk factors (mGPS
score of 1 only if
CRP is elevated)
NA NA
E
llen
G
.
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Table 4 Continued
Variable
Name of Tool (Publication Date)
AAAP
Score13
(2015)
Dorajoo
Score14
(2015)
Maeda
Score15
(2013)
Fendler
Nomogram16
(2015)
RPA,17 GPA18
(1997, 2008)
Dziggel
Score19
(2014)
Rades BM
Score20
(2015)
Pietrantonio
Nomogram21
(2015)
Rades MSCC
Score22 (2012)
GPS,23 mGPS24
(2003, 2007)
Ichikawa
Nomogram25
(2015)
Oncogramme26
(2016)
Prognosis per
category (survival
in development
study)
Median 2-y OS
probability: low
risk, 57%;
moderate risk,
11%; high
risk, 0%
Median CSS:
good, 18 mo;
moderate,
12 mo; poor,
5 mo
Median OS: low
risk, 37 mo;
moderate risk,
22 mo; high risk,
5 mo
NA RPA 6- and 12-mo
OSd: class I, 0%;
class II, 51% and
29%; class III, 22%
and 9%
GPA 6- and 12-mo
OSd: class I, 0%;
class II, 0%; class III,
55% and 30%;
class IV, 24% and
12%
Median 6-mo OS
probability: poor,
11%; moderate,
38%; good, 83%
6- and 12-mo OS
probability: poor,
17% and 0%;
moderate to poor,
25% and 0%;
moderate to good,
67% and 33%;
good, 100% and
67%
NA 6-mo OS probability:
poor, 0%; moderate
to poor, 26%;
moderate to good,
62%; good, 100%
GPS OS: score 0, 20
mo; score 1, 11 mo;
score 2, 7 mo
mGPS CSS: score 0,
454 days; score 1,
504 days; score 2,
253 days
NA NA
Validation population
and model
performance
Validation of
included studies
0 114 0 116 121 119 0 221,27 0 228,29 125 0
Population NA CRC, UR Met,
ER of PT
NA CRC, UR liver Met
refractory to CTx
CRC, SYN or
MC BM
Cancer patients
with BM from less
RS tumors treated
with WBRT
NA CRC, SYN or MC
BM21,27
NA GPS: CRC treated with
5-FUebased CTx and
Bev28; mGPS:
incurable CRC treated
with CTx29
Advanced CRC
treated with
irinotecan-containing
CTx
NA
Patients (n) NA 103 NA 25 227 32 CRC patients NA 11921; 6427 NA GPS, 80; mGPS, 112 350 NA
Years of diagnosis NA 2006-2007 NA 2008-2011 2000-2013 NR NA 2005-201327;
NR21
NA GPS: 2005-2012;
mGPS, 2005-2007
NR NA
Setting NA 1 Hospital,
Singapore
NA 1 Hospital,
Germany
8 Hospitals, Italy NR NA 4 Italian,21 1
Norwegian,27 1
German27 hospital
NA NR 6 institutions,
Japan
NA
Study design NA Retro NA Retro Retro Retro NA Retro21,27 NA Retro Prosp, Observ NA
Discriminatory
accuracy
NA Concordance
probability
estimate, 0.65;
AUC for 6, 12,
18, 24 mo CSS,
0.75; 0.73;
0.71; 0.70
NA C-index, 0.83
(95% CI, 0.62-
1.05)
C-index: RPA,
0.61; GPA, 0.59
6-mo OS differed
among 3
prognostic
categories
(log-rank test;
P ¼ .003)
NA C-index, 0.7321 NA GPS/mGPS: prognosis
differed between
prognostic categories
(P <.05)
C-index, 0.70 NA
Van Calster level
of calibrationb
NA No calibration
measures
reported
NA No calibration
measures reported
No calibration
measures reported
No calibration
measures
reported
NA Moderate21 NA No calibration
measures reported
Weak NA
Reilly level of
evidencec
1 2 1 1 RPA: 2; GPA: 2 1 1 2 1 GPS: 1; mGPS: 1 2 1
User-friendliness
Predictors
routinely collected
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Not UGT1A1 No, test kit must be
purchased
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Ellen G. Engelhardt et alThe RPA and GPA have been validated in a large number of studies.
However, except for the study by Pietrantonio et al,21 small numbers
(generally < 20) of incurable mCRC patients were included the
validation cohorts. Also, only the tools’ performance in the whole
cohort was reported, not speciﬁcally their performance in incurable
metastasized CRC patients. Brain metastases are not frequently
observed in CRC patients, and they might respond differently to
treatment than brain metastases from other primary tumor locations.
Pietrantonio et al21 reported poor to moderate discriminatory accu-
racy for the RPA and GPA (C-index for RPA, 0.59 and for GPA,
0.61), and their calibration was not reported (Table 4).
Simultaneously, Pietrantonio et al21 also reported on the
development and validation of a new nomogram that predicts the
median overall survival for CRC patients with brain metastases.
This tool aids oncologists in determining which patients will
beneﬁt most from invasive treatment directed at limiting tumor
growth, combined with symptom relief, and which patients will be
best served with less-invasive treatments (eg, symptom relief only).
The discriminatory accuracy of this nomogram in the Italian
external validation population was good (Harrels’ C-index, 0.73);
however, the calibration plot showed that the congruence between
the predicted and observed survival was generally poor.21 An
external validation study using a cohort of Norwegian and German
patients also found that the model calibration was poor.27 It
underestimated the survival of patients treated with stereotactic
surgery by a median of 4.2 months and overestimated survival for
those who had undergone whole brain radiotherapy by a median of
2.1 months.27
Dziggel et al19 developed a prognostic score to aid treatment
decision-making for patients with brain metastases from less-
radiosensitive primary tumors (Table 4). This prognostic score
was developed (n ¼ 34) and validated (n ¼ 32) in small samples of
CRC patients. The methods used to determine discriminatory ac-
curacy were poor, and calibration was not reported for this DSS.
Rades et al20 developed a tool to aid in the selection of CRC
patients with brain metastases who could beneﬁt from stereotactic
surgery. This tool was developed in a cohort of only 19 patients
and has not been externally validated (Table 4). Rades et al22 also
developed a tool to aid in palliative radiotherapy decision-making
for CRC patients with spinal cord compression due to spinal
metastases (n ¼ 121); that DSS also has not been externally
validated.DSS Predicting the Risk of Side Effects. Ichikawa et al25 developed
a nomogram to predict the probability of severe neutropenia
during the ﬁrst cycle of treatment with irinotecan for incurable
mCRC patients (Table 4). This nomogram was developed and
validated in Japanese patients, and the discriminatory accuracy was
a C-index of 0.70. Calibration was good in the development
population (n ¼ 1312), but was not reported in the validation
population (n ¼ 350).DSS Predicting Response to Systemic Treatment. Recently, a
chemotherapy sensitivity and resistance assay,26 Oncogramme, was
developed to help oncologists in the selection of the systemic
therapy regimen to which the patient’s tumor would be mostClinical Colorectal Cancer March 2018 - e9
Figure 3 Overview of the Frequency With Which Predictors Were Included in Decision Support System (DSS) for Incurable Metastatic
Colorectal Cancer Patients
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e10 -sensitive (Table 4). A proof of concept trial with a small sample of
patients (n ¼ 19) showed that this assay has good sensitivity
(85%); however, the speciﬁcity was very low (33%). The
congruence between the predicted and observed chemotherapy
sensitivity was moderate (63%). The investigators reported plans
for a large trial to obtain more insight regarding the usefulness of
this tool.
User-friendliness of DSSs
Generally, the predictors incorporated in the DSSs identiﬁed
were routinely collected in clinical practice (Table 4). Only the
nomogram by Ichikawa et al25 incorporated a genetic marker that is
not yet routinely collected in clinical practice (ie, UGT1A1 geno-
type). None of the DSSs were available as online tools. Although allClinical Colorectal Cancer March 2018DSSs can be derived from the development and/or validation re-
ports, for 4 of the prognostic scores,13,19,20,22 the scoring system
and the breakdown into prognostic categories could not always be
easily extracted from the reports.
Discussion
We performed a systematic review of the published data to obtain
a comprehensive overview of the DSSs available to aid oncologists
with palliative treatment decision-making for patients with incur-
able mCRC. We have provided insight into the characteristics of the
available DSSs, their discriminatory accuracy and calibration, and
their ease of use in clinical practice. Only 14 DSSs for patients with
incurable mCRC were identiﬁed. The systematic search yielded
many more DSSs aiming to guide treatment decision-making for
Ellen G. Engelhardt et almCRC patients who might still be cured (eg, the Köhne score)
using treatments such surgery with curative intent for solitary liver
metastases or hyperthermic intraperitoneal chemotherapy plus
cytoreductive surgery for peritoneal metastases. DSSs for treatments
with a curative intent were not included in the present systematic
review because our aim was to assess the state-of-the-art regarding
DSSs for palliative treatment decision-making.
None of the DSSs for patients with incurable mCRC compared
multiple treatment options. Of the 14 DSSs, 12 either aimed to help
oncologists form an opinion on whether 1 speciﬁc treatment or
further invasive palliative treatment in general is worthwhile, given
the prognosis. One DSS assessed the risk of developing severe
irinotecan-induced neutropenia, and one tool created individual
chemotherapy sensitivity and resistance tumor proﬁles. We found no
tool that encompassed multiple palliative treatment options available
for incurable mCRC. Also, no repository containing all available
DSSs for the palliative setting exists. Therefore, potentially infor-
mative resources might not ﬁnd their way into clinical practice unless
they have been incorporated into clinical treatment guidelines.
Furthermore, most of the tools focused on predicting survival.
None presented both the beneﬁts and harms of treatment. This is
problematic, because DSSs are used by clinicians before patient
consultations to better conceptualize the trade-off between the
beneﬁts and harms involved in treatment. DSSs can also be used
during patient consultations to inform patients about their prog-
nosis and help them to participate in the decision-making process. If
DSSs only present the treatment beneﬁts, it could cause both on-
cologists and patients to lose sight of the potential harms of the
treatment modalities that target tumor progression. Maintaining
and/or improving patients’ quality of life is paramount and should
be the cornerstone of palliative treatment decisions, in addition to
patients’ preferences. Additionally, other outcomes, such as quality-
adjusted life expectancy, which are of interest from a societal and
policy perspective were not included in any of the DSSs.
The predictors included in the DSSs varied greatly. Only age,
performance status, and location of distant metastases were incor-
porated in  5 DSS. This in itself is not surprising because the
DSSs have different aims. However, it is surprising that the pre-
dictors evaluated and those incorporated into the ﬁnal model also
varied among the DSSs that have the same aim (eg, the AAAP score,
Dorajoo score, and Maeda score). This can be explained in part
because almost all development studies had a retrospective design,
which, thus, limited the availability of predictors. This could
negatively affect a DSS’ predictive ability. Furthermore, although 10
of 14 DSSs were developed within the past 5 years, only the
nomogram by Ichikawa et al25 included a genetic marker (ie,
UGT1A1 genotype). None of the DSSs included known clinically
signiﬁcant oncogenes (ie, KRAS, BRAF, or PIK3CA) or tumor
suppressor genes (ie, APC, TP53, or PTEN ).31-35 Rapid de-
velopments in this ﬁeld might make it difﬁcult for DSS developers
to remain current because the development and validation of DSSs
are time-consuming processes. However, the addition of tumor
markers could improve the discriminatory accuracy of DSSs.
Currently, evidence on DSS performance is limited owing to un-
clear reporting and methodologic problems. For example, some
studies did not report basic characteristics regarding the patient
population, such as the setting or year of diagnosis. Of the 14 tools, 9only reached a Reilly level of evidence of 1, and 5 reached a level 2;
thus, the DSSs were either not externally validated or only in a
population very similar to the population in which the DSS was
developed. Validation in > 1 ethnic population is also important
because the medication metabolism and the probabilities of compli-
cations from surgery can differ owing to genetic and/or morphologic
differences.36,37 Three tools had been externally validated but were
considered level 1, because the validation was poor (ie, the sample size
was small [n ¼ 25 and n ¼ 32]) and/or the method was not sound.
The method for determining the discriminatory accuracy of the DSSs
varied among the studies, some investigators used Kaplan-Meier
curves and log-rank tests, and others used receiver operating charac-
teristic curves and C-indexes. Only 2 studies reported on the cali-
bration, although this is an important measure ofmodel performance.
Moreover, the DSSs were developed for different purposes, andmany
were not externally validated. This makes it difﬁcult to perform a
meta-analysis or direct comparisons among DSSs.
The strength of the present review was the application of a
broad search strategy to ﬁnd all relevant tools. However, the lack
of uniformity in terminology made it difﬁcult to formulate a
search strategy encompassing all relevant terms. This might have
subverted our intent to retrieve all relevant DSSs. It is imperative
that investigators work toward uniformity in terminology. Also, we
had intended to use the CHARMS checklist38 (checklist for crit-
ical appraisal and data extraction for systematic reviews of pre-
diction modelling studies) to gain insights into the methodologic
soundness of the DSSs. In preparation for the data extraction, we
found that a large number of items included in the CHARMS
checklist had not been reported or were not relevant to our pur-
poses. Therefore, we opted to use a self-developed abbreviated
version of the CHARMS checklist containing only the main points
reported in Table 3.
Conclusion
The present review is, to the best of our knowledge, the ﬁrst to
provide a comprehensive overview of available DSSs aiming to aid
oncologists’ palliative treatment decision-making in the context of
incurable mCRC. Our ﬁndings highlight the need for rigorously
developed and validated comprehensive DSSs that compare multiple
treatment options and provide insights regarding the beneﬁts and
harms of the treatment options. Ideally, newly developedDSSs would
be continuously updated to keep up with the rapid developments in
treatment. Embedding DSSs into national patient registries could
facilitate their continuous update. Without exception, the use of
existing DSSs in clinical practice cannot be recommended before
establishing whether their discriminative ability is good and/or they
have been validated in a broad range of populations (eg, different
settings and ethnicities). Finally, impact studies are needed to gain
insight into the effect of DSSs on clinical decision-making.
Clinical Practice Points
 Palliative treatment decision-making for mCRC is complex.
 DSSs, such as nomograms, can facilitate decision-making.
 Fourteen DSSs are available to aid decision-making regarding
palliative treatment.
 None of available DSSs are currently appropriate for use in
clinical practice.Clinical Colorectal Cancer March 2018 - e11
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e12 - High-quality DSSs presenting both the beneﬁts and the harms of
treatment are needed.Acknowledgments
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